Next generation therapies change the landscape in melanoma

por Flaherty, Keith T.
Publicado 2011

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

por Sullivan, Ryan J., Flaherty, Keith T.
Publicado 2011

Mechanisms of resistance to immune checkpoint inhibitors

por Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Publicado 2018

The Conundrum of Genetic “Drivers” in Benign Conditions

por Kato, Shumei, Lippman, Scott M., Flaherty, Keith T., Kurzrock, Razelle
Publicado 2016

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

por Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Publicado 2015

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

por Fedorenko, Inna V., Wargo, Jennifer A., Flaherty, Keith T., Messina, Jane L., Smalley, Keiran S.M.
Publicado 2015

A Melanoma Molecular Disease Model

por Vidwans, Smruti J., Flaherty, Keith T., Fisher, David E., Tenenbaum, Jay M., Travers, Michael D., Shrager, Jeff
Publicado 2011

Selective uveal melanoma inhibition with calcium channel blockade

por SHAUGHNESSY, MICHAEL, LAMURAGLIA, GRACE, KLEBANOV, NIKOLAI, JI, ZHENYU, RAJADURAI, ANPUCHCHELVI, KUMAR, RAJ, FLAHERTY, KEITH, TSAO, HENSIN
Publicado 2019

Pathways and therapeutic targets in melanoma

por Shtivelman, Emma, Davies, Michael A., Hwu, Patrick, Yang, James, Lotem, Michal, Oren, Moshe, Flaherty, Keith T., Fisher, David E.
Publicado 2014

Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma

por Romano, David, García-Gutiérrez, Lucía, Aboud, Nourhan, Duffy, David J, Flaherty, Keith T, Frederick, Dennie T, Kolch, Walter, Matallanas, David
Publicado 2022

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high)/AXL(low) melanoma

por Smith, Michael P., Rana, Sareena, Ferguson, Jennifer, Rowling, Emily J., Flaherty, Keith T., Wargo, Jennifer A., Marais, Richard, Wellbrock, Claudia
Publicado 2018

MITF Modulates Therapeutic Resistance through EGFR Signaling

por Ji, Zhenyu, Chen, Yiyin Erin, Kumar, Raj, Taylor, Michael, Njauw, Ching-Ni Jenny, Miao, Benchun, Frederick, Dennie T., Wargo, Jennifer A., Flaherty, Keith T., Jönsson, Göran, Tsao, Hensin
Publicado 2015

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado 2013

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a...

por Ascierto, Paolo A., Ribas, Antoni, Larkin, James, McArthur, Grant A., Lewis, Karl D., Hauschild, Axel, Flaherty, Keith T., McKenna, Edward, Zhu, Qian, Mun, Yong, Dréno, Brigitte
Publicado 2020

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

por Johannessen, Cory M., Johnson, Laura A., Piccioni, Federica, Townes, Aisha, Frederick, Dennie T., Donahue, Melanie K., Narayan, Rajiv, Flaherty, Keith T., Wargo, Jennifer A., Root, David E., Garraway, Levi A.
Publicado 2013

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase...

por O'Reilly, Eileen M., Roach, James, Miller, Paul, Yu, Kenneth H., Tjan, Catherine, Rosano, Molly, Krause, Silva, Avery, William, Wolf, Julie, Flaherty, Keith, Nix, Darrell, Ryan, David P.
Publicado 2017

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

por Desai, Brijal M., Villanueva, Jessie, Nguyen, Thierry-Thien K., Lioni, Mercedes, Xiao, Min, Kong, Jun, Krepler, Clemens, Vultur, Adina, Flaherty, Keith T., Nathanson, Katherine L., Smalley, Keiran S. M., Herlyn, Meenhard
Publicado 2013

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

por Moschos, Stergios J., Sandhu, Shahneen, Lewis, Karl D., Sullivan, Ryan J., Puzanov, Igor, Johnson, Douglas B., Henary, Haby A., Wong, Hansen, Upreti, Vijay V., Long, Georgina V., Flaherty, Keith T.
Publicado 2022

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

por Jilaveanu, Lucia B., Zhao, Fengmin, Zito, Christopher R., Kirkwood, John M., Nathanson, Katherine L., D'Andrea, Kurt, Wilson, Melissa, Rimm, David L., Flaherty, Keith T., Lee, Sandra J., Kluger, Harriet M.
Publicado 2013

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

por Lewis, Karl D., Larkin, James, Ribas, Antoni, Flaherty, Keith T., McArthur, Grant A., Ascierto, Paolo A., Dréno, Brigitte, Yan, Yibing, Wongchenko, Matthew, McKenna, Edward, Zhu, Qian, Mun, Yong, Hauschild, Axel
Publicado 2019